Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Publication year range
1.
Mil Med Res ; 7(1): 25, 2020 06 03.
Article in English | MEDLINE | ID: mdl-32493477

ABSTRACT

BACKGROUND: Tuberculosis is a leading cause of death worldwide. BCG is an effective vaccine, but not widely used in many parts of the world due to a variety of issues. Mycobacterium vaccae (M. vaccae) is another vaccine used in human subjects to prevent tuberculosis. In the current study, we investigated the potential mechanisms of M. vaccae vaccination by determining differentially expressed genes in mice infected with M. tuberculosis before and after M. vaccae vaccination. METHODS: Three days after exposure to M. tuberculosis H37Rv strain (5 × 105 CFU), adult BALB/c mice randomly received either M. vaccae vaccine (22.5 µg) or vehicle via intramuscular injection (n = 8). Booster immunization was conducted 14 and 28 days after the primary immunization. Differentially expressed genes were identified by microarray followed by standard bioinformatics analysis. RESULTS: M. vaccae vaccination provided protection against M. tuberculosis infection (most prominent in the lungs). We identified 2326 upregulated and 2221 downregulated genes in vaccinated mice. These changes could be mapped to a total of 123 signaling pathways (68 upregulated and 55 downregulated). Further analysis pinpointed to the MyD88-dependent TLR signaling pathway and PI3K-Akt signaling pathway as most likely to be functional. CONCLUSIONS: M. vaccae vaccine provided good protection in mice against M. tuberculosis infection, via a highly complex set of molecular changes. Our findings may provide clue to guide development of more effective vaccine against tuberculosis.


Subject(s)
BCG Vaccine/adverse effects , Mycobacteriaceae/drug effects , Tuberculosis/prevention & control , Adjuvants, Immunologic/adverse effects , Adjuvants, Immunologic/pharmacology , Adjuvants, Immunologic/therapeutic use , Animals , BCG Vaccine/pharmacology , BCG Vaccine/therapeutic use , Disease Models, Animal , Mice , Mice, Inbred BALB C , Tuberculosis/drug therapy , Tuberculosis/immunology , Up-Regulation/drug effects , Up-Regulation/genetics
2.
Zhongguo Shi Yan Xue Ye Xue Za Zhi ; 17(6): 1492-6, 2009 Dec.
Article in Chinese | MEDLINE | ID: mdl-20030933

ABSTRACT

The aim of this study was to investigate the immune regulatory effect of dendritic cells phagocytosing photochemotherapy-treated allogeneic spleen lymphocytes on syngeneic T cells. DA rat spleen lymphocytes were treated with 8-methoxypsoralen plus UVA irradiation (PUVA). LEW rat bone marrow-derived DCs were co-cultured with PUVA-treated DA spleen lymphocytes (PUVA-SP), and the surface markers (MHC-II, CD86 and CD40) of treated DC were detected by flow cytometry. CFSE-labeled PUVA SP were incubated with LEW DCs and the phagocytosis of DCs on PUVA-SP was observed by using fluorescent microscope. The ability of DC phagocytosing allogeneic PUVA-SP (PUVA-SP DC) to stimulate the proliferation of LEW T cells was analyzed by mixed leukocyte reactions (MLR). The production of IL-4, IL-10, IL-2, IFN-gamma in MLR culture supernatant was determined by luminex method. The results indicated that the PUVA treatment effectively induced early apoptosis of DA rat spleen lymphocytes. After co-culture, DC efficiently phagocytosed allogeneic PUVA-SP and still maintained an immature phenotype with low levels of MHC II, CD40 and CD86. PUVA-SP DC induced LEW T cell hyporesponsiveness to DA rat antigen, and led to skewing of T cell cytokine expression toward Th2 (IL-10 and IL-4). It is concluded that the PUVA-SP DC effectively down-regulate T cell response to alloantigen and induce Th2 immune deviation in vitro.


Subject(s)
Dendritic Cells/immunology , Dendritic Cells/physiology , Phagocytosis/immunology , T-Lymphocytes/immunology , Animals , Dendritic Cells/cytology , Flow Cytometry , Isoantigens , Photochemistry , Rats , Rats, Inbred Lew
3.
Zhonghua Fu Chan Ke Za Zhi ; 42(10): 701-4, 2007 Oct.
Article in Chinese | MEDLINE | ID: mdl-18241548

ABSTRACT

OBJECTIVE: To investigate the impact of danazol alginate microspheres used for uterine arterial embolization (UAE) on ovarian function and subsequent pregnancy using rabbit as a model. METHODS: A total of 32 female rabbits were divided into 3 groups: a control group, danazol alginate microspheres (DKMG) group and alginate microspheres (KMG) group. Basal serum estradiol (E(2)), follicle stimulating hormone (FSH), luteinizing hormone (LH), testosterone (T) levels before UAE and 1 - 3 months after UAE were compared for all rabbits. In breeding field all rabbits mated after UAE. Estrus, and pregnancy rate were observed by veterinary. RESULTS: There were no significant changes from baseline FSH, LH, E(2), T levels measured at 1, 2 and 3 months after UAE (P > 0.05). The total pregnancy rate of DKMG or KMG group was 0 within 2 - 4 months after UAE. Compared to the control group (4/8), the difference was statistically significant (P < 0.05); the total pregnancy rate of DKMG, KMG and control groups within 5 - 7 months after UAE, respectively 17% (2/12), 25% (3/12) and 5/8 (P > 0.05); the total pregnancy rate was 42% (5/12), 50% (6/12) and 6/8 respectively within 8 - 10 months after UAE, there were also no significant differences between the three groups (P > 0.05). CONCLUSIONS: There is no obvious effect of danazol alginate microspheres used for uterine arterial embolization on ovarian function in rabbits. After UAE some animals are able to achieve pregnancies, while harmful effects are observed on short term pregnant rate.


Subject(s)
Danazol/therapeutic use , Embolization, Therapeutic/methods , Leiomyoma/therapy , Ovary/drug effects , Uterine Neoplasms/therapy , Alginates/administration & dosage , Alginates/therapeutic use , Animals , Danazol/administration & dosage , Embolization, Therapeutic/adverse effects , Estradiol/blood , Female , Follicle Stimulating Hormone/blood , Leiomyoma/blood , Luteinizing Hormone/blood , Microspheres , Ovary/physiopathology , Pregnancy , Pregnancy Rate , Rabbits , Treatment Outcome , Uterine Neoplasms/blood , Uterus/blood supply , Uterus/drug effects , Uterus/pathology
4.
Oncogene ; 22(3): 467-70, 2003 Jan 23.
Article in English | MEDLINE | ID: mdl-12545169

ABSTRACT

Frequent loss of heterozygosity (LOH) on human chromosome 7q31 has been reported in numerous malignancies. Suppressor of tumorigenicity 7 (ST7) has been identified as a candidate tumor suppressor gene in this region. To identify whether 7q31 and genetic alterations of ST7 were involved in human esophageal carcinogenesis, we performed LOH mapping of a 5.4 cM region at 7q31-q35 in 43 primary esophageal carcinomas, as well as mutational analyses of the ST7 gene in tumors with LOH in this region. Of 43 tumors, 12 (28%) showed LOH at 7q31-q35. These included four (22%) of 18 squamous cell carcinomas and eight (32%) of 25 adenocarcinomas. The peak LOH locus was D7S480, lying 4.2 Mb telomeric to ST7 and showing LOH in eight of 37 informative tumors, or 22%. No mutations were found in the entire coding or flanking intronic regions of the ST7 gene among 12 tumors with 7q-LOH. In addition, quantitative RT-PCR analyses of ST7 mRNA expression levels in 11/13 normal-tumor pairs failed to show more than a 50% decrease in tumor ST7 mRNA relative to matched normal tissues. These data suggest that LOH at 7q31-q35 is involved in the origin or progression of at least a subset of esophageal carcinomas, but that ST7 is not the target gene of this somatic event.


Subject(s)
Carcinoma/genetics , Esophageal Neoplasms/genetics , Loss of Heterozygosity , Mutation , Proteins/genetics , Tumor Suppressor Proteins , Adenocarcinoma/genetics , Chromosomes, Human, Pair 7 , DNA, Intergenic , Gene Expression Regulation, Neoplastic , Humans , Introns , Neoplasms, Squamous Cell/genetics , Quantitative Trait Loci , Reference Values , Sequence Analysis, DNA
SELECTION OF CITATIONS
SEARCH DETAIL
...